Among medications, antidepressants take the prize for inciting public and media mood swings. Whether celebrated as depression-busting happy pills or dismissed as overrated and apt to cause dangerous side effects, selective serotonin reuptake inhibitors (SSRIs) have taken pharmaceutical firms on a financial joy ride. Since their U.S.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.